DISC MEDICINE INC (IRON)
US2546041011 - Common Stock
Noteworthy Monday Option Activity: ZIP, PAYX, IRON
Monday Sector Laggards: Biotechnology, Water Utilities
Disc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity Study
The company is hoping to treat a rare disease that causes patients to experience severe reactions to sunlight.
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On track to...
Noteworthy Wednesday Option Activity: IRON, CRNX, WGO
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...
Notable Friday Option Activity: SLG, IRON, FANG
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous...
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
WATERTOWN, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to DISC-0974 for the treatment of patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemia.
Notable Friday Option Activity: RCL, IRON, CHK
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...
Disc Medicine appoints Jean Franchi as CFO (NASDAQ:IRON)
Disc Medicine appoints Jean Franchi as CFO, succeeding Joanne Bryce. Franchi was previously CFO of Replimune.
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at...
Commit To Purchase Disc Medicine At $45, Earn 15% Annualized Using Options
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...
Noteworthy Thursday Option Activity: IRON, CPRI, MSFT
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (“Disc”), a clinical-stage biopharmaceutical company focused on the...
Noteworthy Wednesday Option Activity: IRON, IIPR, ABM
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
Updated data from BEACON continued to demonstrate significant, consistent reductions in protoporphyrin IX (PPIX) > 40% and improvements in sunlight...
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
Substantial, dose-dependent reductions in serum hepcidin and increases in serum iron Hematologic response demonstrated by increased hemoglobin levels and...
NASDAQ:IRON Shareholder Notice: Investigation over Potential Wrongdoing at Disc Medicine Opco Inc
San Diego, CA -- (SBWIRE) -- 12/08/2023 -- Certain directors of Disc Medicine Opco Inc are under investigation over potential breaches of fiduciary duties.